Loading…
StockAnalyzerLoading…
Aspen Neuroscience, Inc. develops autologous induced pluripotent stem cell (iPSC)-derived cell replacement therapies for neurodegenerative diseases. The company's develops ANPD001, an investigational single-dose, autologous dopaminergic neuronal precursor cell (DANPC) therapy for Parkinson's disease. It operates in the United States. The company also advances additional cell replacement candidates targeting both sporadic and genetic forms of Parkinson's disease, as well as other candidates for conditions of the central nervous system (CNS). Aspen Neuroscience, Inc. was formerly known as Aspen Biosciences, Inc. and changed its name to Aspen Neuroscience, Inc. in October 2018. Aspen Neuroscience, Inc. was incorporated in 2018 and is based in San Diego, California.
www.aspenneuroscience.com ↗| Mr. Faheem Hasnain | Executive Chairman | 67 | 35,000 USD |
| Dr. Damien McDevitt Ph.D. | President, CEO & Director | 58 | 954,101 USD |
| Prof. Jeanne F. Loring Ph.D. | Co-Founder & Member of Scientific Advisory Board | — | — |
| Mr. Kim Raineri M.B.A. | Chief Technology Officer | — | 622,452 USD |
| Ms. Xiaokui Zhang Ph.D. | Chief Scientific Officer | — | — |
| Ms. Samantha Murphy Ph.D. | Senior Vice President of Corporate Development | — | — |
| Ms. Jennifer Whitaker | Vice President of Human Resources | — | — |
| Mr. Andres Bratt-Leal Ph.D. | Senior Vice President of Research & Development | — | — |
| Dr. Lisa R. Johnson-Pratt M.D. | Sasineprocel Development Lead & Chief Commercial Officer | 61 | — |
| Dr. Revati Shreeniwas FCCP, M.D., Ph.D. | Chief Medical Officer | 64 | — |
| Year | Buybacks | Dividends | Acquisitions |
|---|---|---|---|
| 2024 | — | — | — |
| 2025 | — | — | — |